Abstract
Because allergic disorders can be a significant burden to patients, efforts have been directed to understanding the mechanisms of allergic disorders to develop more rational therapeutic interventions. Immunotherapy aims to prevent the immunological reaction of allergy sufferers to specific allergens. Immunotherapy is indicated for the treatment of allergic rhinitis and allergic asthma and may prevent development of asthma in patients with allergic rhinitis. The current standard therapy is subcutaneous administration of clinically relevant allergens for several months, building up to eventual monthly injections lasting typically 3 to 5 years. However, subcutaneous immunotherapy (SCIT) has several disadvantages such as a higher risk of anaphylaxis and must be performed only in a clinician’s office with adequate personnel Comparison of Patient Satisfaction between Subcutaneous Immunotherapy and Sublingual Immunotherapy in Allergic Rhinitis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
